Market Closed -
Canadian Securities Exchange
07:00:00 27/04/2023 pm IST
|
5-day change
|
1st Jan Change
|
0.045
CAD
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Capitalization
1 |
144
|
34.72
|
75.48
|
24.43
|
6.108
|
Enterprise Value (EV)
1 |
140.6
|
34.39
|
74.7
|
29.53
|
13.35
|
P/E ratio
|
-32.5
x
|
-5.61
x
|
-18.9
x
|
-1.5
x
|
-0.61
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
32,01,33,257
x
|
2,86,85,688
x
|
60,54,859
x
|
EV / Revenue
|
-
|
-
|
31,68,10,232
x
|
3,46,64,561
x
|
1,32,36,042
x
|
EV / EBITDA
|
-62.4
x
|
-6.5
x
|
-14.4
x
|
-7.09
x
|
-4.45
x
|
EV / FCF
|
301
x
|
-11.6
x
|
-15.1
x
|
185
x
|
-7.14
x
|
FCF Yield
|
0.33%
|
-8.65%
|
-6.62%
|
0.54%
|
-14%
|
Price to Book
|
18.1
x
|
5.99
x
|
5.23
x
|
2.39
x
|
50.3
x
|
Nbr of stocks (in thousands)
|
13,719
|
14,171
|
17,155
|
20,361
|
20,361
|
Reference price
2 |
10.50
|
2.450
|
4.400
|
1.200
|
0.3000
|
Announcement Date
|
30/04/18
|
29/04/19
|
28/04/20
|
30/04/21
|
29/04/22
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net sales
|
-
|
-
|
-
|
0.2358
|
0.8518
|
1.009
|
EBITDA
1 |
-0.9863
|
-2.255
|
-5.289
|
-5.184
|
-4.163
|
-3.003
|
EBIT
1 |
-0.9876
|
-2.258
|
-5.551
|
-5.493
|
-4.659
|
-3.447
|
Operating Margin
|
-
|
-
|
-
|
-2,329.93%
|
-547.03%
|
-341.73%
|
Earnings before Tax (EBT)
1 |
-1.18
|
-4.438
|
-6.078
|
-3.698
|
-15.05
|
-13.85
|
Net income
1 |
-1.18
|
-4.438
|
-6.078
|
-3.698
|
-14.33
|
-10.06
|
Net margin
|
-
|
-
|
-
|
-1,568.6%
|
-1,682.88%
|
-997.36%
|
EPS
2 |
-0.9610
|
-0.3234
|
-0.4368
|
-0.2325
|
-0.8000
|
-0.4942
|
Free Cash Flow
1 |
-0.6696
|
0.4671
|
-2.974
|
-4.948
|
0.1592
|
-1.869
|
FCF margin
|
-
|
-
|
-
|
-2,098.67%
|
18.69%
|
-185.25%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/11/17
|
30/04/18
|
29/04/19
|
28/04/20
|
30/04/21
|
29/04/22
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
5.09
|
7.24
|
Net Cash position
1 |
0.4
|
3.46
|
0.33
|
0.78
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-1.223
x
|
-2.412
x
|
Free Cash Flow
1 |
-0.67
|
0.47
|
-2.97
|
-4.95
|
0.16
|
-1.87
|
ROE (net income / shareholders' equity)
|
-40.1%
|
-77.5%
|
-88.2%
|
-36.5%
|
-114%
|
-367%
|
ROA (Net income/ Total Assets)
|
-19.4%
|
-23.5%
|
-47.3%
|
-32.5%
|
-17.3%
|
-17%
|
Assets
1 |
6.089
|
18.91
|
12.84
|
11.38
|
83.07
|
59.1
|
Book Value Per Share
2 |
0.1700
|
0.5800
|
0.4100
|
0.8400
|
0.5000
|
0.0100
|
Cash Flow per Share
2 |
0.0200
|
0.2500
|
0.0200
|
0.0500
|
0.0100
|
0.0100
|
Capex
1 |
0.19
|
1.32
|
0.36
|
2.29
|
0.34
|
0.22
|
Capex / Sales
|
-
|
-
|
-
|
970.93%
|
39.84%
|
21.9%
|
Announcement Date
|
03/11/17
|
30/04/18
|
29/04/19
|
28/04/20
|
30/04/21
|
29/04/22
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 1.93M | | +43.25% | 6.3B | | -15.08% | 4.44B | | -6.70% | 3.27B | | +5.47% | 3.16B | | +0.76% | 2.58B | | +47.75% | 1.96B | | -5.08% | 1.73B | | +2.05% | 1.68B | | -7.08% | 1.63B |
Alternative Medicine
|